Glaukos addressed investors at the Wells Fargo healthcare conference, framing its story around commercial launch ramps alongside persistent reimbursement risks.
For early-stage medtech and healthtech founders, this is a stark reminder that regulatory clearance or initial clinical traction is only half the battle. You can build a category-defining product and initiate a rollout, but if third-party payors drag their feet on coverage or alter codes, your commercial growth flattens overnight.
For retail backers and venture investors, public market sensitivity to payor friction signals a key risk for early-stage deal pricing. When established public players flag reimbursement as a core operational headwind, growth-stage capital demands higher margins of safety, pushing down valuations for startups that haven't fully derisked their monetization pathways.
Generating hype around a product launch gets you through the door, but proving long-term payor buy-in is what actually protects your runway and keeps your cost of capital down.